Firefly Neuroscience Reports 373% Year-Over-Year Increase in U18 ADHD Evoke™ Scans
Firefly Neuroscience announced a 373% year-over-year increase in U18 ADHD Evoke™ scan volume, highlighting the company's accelerating commercial expansion.
Stocks · News reference
Firefly Neuroscience announced its financial results for the third quarter of 2026, highlighting significant revenue growth and improved profit margins.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Firefly Neuroscience announced a 373% year-over-year increase in U18 ADHD Evoke™ scan volume, highlighting the company's accelerating commercial expansion.
Firefly Neuroscience announced a strategic focus on its Brain-Computer Interface (BCI) growth, supported by its AI foundation model and the commercial availability of its Versus platform.
U.S. stock futures fell as gold and silver prices slid, sending Gold Fields down 16% and other precious-metal stocks lower in premarket trading.
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.